MNPR

AI Memo

Monopar Therapeutics

As of 2026-10-02/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-02 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Complete the rolling ALXN1840 NDA submission • 2026-11-30

Base target: $85 / p=50% prob

Biggest risk

NDA completion, filing acceptance, approval and commercial uptake are separate hurdles. Q2 net loss increased to $5.3 million from $2.5 million a year earlier, while R&D expense rose to $4.77 million from $1.73 million. No verified analyst revisions or post-results consensus comparison are available. [#PR-EARNINGS-2026-08-12] Company release

Invalidation

Break below $42 or thesis failure.

What would change my mind?

The Phase 3 FoCus trial met its primary copper-mobilization endpoint, and the rolling NDA plus launch preparations give ALXN1840 a tangible regulatory path. The June cash position supports planned operations through at least December 2027, according to the company. [#PR-EARNINGS-2026-08-12] Company release

Research note

Recommendation

—

Confidence

medium

As of

2026-10-02

Base target

$85

p=50%

Bull target

$125

p=25%

Bear target

$42

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

ALXN1840 AASLD abstracts and presentations
Conditional FDA review and commercial transition
The Phase 3 FoCus trial met its primary copper-mobilization endpoint, and the rolling NDA plus launch preparations give ALXN1840 a tangible regulatory path.

BearKey bullets

Approval would not ensure reimbursement, competitive pricing or patient uptake.
Company release
FDA may decline to accept the completed NDA, request additional work or deny approval; rolling submission is not filing acceptance.

WatchKey bullets

Complete the rolling ALXN1840 NDA submission

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $85 (p=50%)

Target spread vs base: +47% / -51%

Scenario probabilities

Bull Target: $125 (p=25%)Base Target: $85 (p=50%)Bear Target: $42 (p=25%)

Commentary

The packet contains no recent-news or sufficient social sample, and the sentiment numbers are unmeasured placeholders, not observed neutral readings. The anchor fell from the prior baseline's $85.235 September 25 price to $77.97 on October 1, about 8.5%; the packet does not establish a cause. Analyst revisions and an earnings-surprise comparison are unavailable. Primary sources support regulatory progress, but independent coverage and forward visibility remain thin.

As of 2026-10-02 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

ALXN1840 AASLD abstracts and presentations
Conditional FDA review and commercial transition

Scenarios

Bull Target (Scenario probability)

$125 / p=25% prob

Base Target (Scenario probability)

$85 / p=50% prob

Bear Target (Scenario probability)

$42 / p=25% prob

Analysis 2026-10-02 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-11-30
Complete the rolling ALXN1840 NDA submission
Monopar began its Wilson disease NDA submission in July and said in August that it expected to complete it within the next few months. The date is an estimate; completion would not mean FDA filing acceptance or approval. [#PR-EARNINGS-2026-08-12] [#8-K-2026-08-12] Company release
Prob 65.00% • Move 15.00% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

ALXN1840 AASLD abstracts and presentations
2026-10-05
The company said two ALXN1840 abstracts were accepted for the November 5–9 meeting, with abstracts scheduled for public release October 5. Incremental clinical or regulatory significance is not yet established. [#IR-2026-08-19] Company release
Prob 90% • Move 5% • Priced-in 70%

Long-term Catalysts

Months to a year

Conditional FDA review and commercial transition
2027-12-31
Monopar is preparing for a potential ALXN1840 launch. It reported $134.3 million in cash, equivalents and investments at June 30 and expected funding through at least December 2027. FDA acceptance, approval, reimbursement and uptake remain uncertain; the date is a monitoring horizon, not an announced decision date. [#PR-EARNINGS-2026-08-12] Company release
Prob 40% • Move 35% • Priced-in 35%

Risks

Approval would not ensure reimbursement, competitive pricing or patient uptake. Company release
FDA may decline to accept the completed NDA, request additional work or deny approval; rolling submission is not filing acceptance. Company release
Higher R&D spending and prelaunch costs could shorten the company's stated funding horizon or require financing. Company release
The September 24 CEO Form 4 reports option exercises alongside open-market sales; these transactions do not establish operating deterioration. [#SEC-FORM4-2026-09-28]

Peers

Symbol	Summary
CAPR	Similar-sized clinical-stage biopharma, but its indication and regulatory path differ; a loose financing and risk-appetite comparison, not a Wilson disease valuation peer.
EPRX	Similar-sized development-stage biopharma, but product economics and indication comparability are unverified. Do not transfer its valuation multiple to MNPR.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-02

Loading AI feed…

Symbol

Summary

CAPR

Similar-sized clinical-stage biopharma, but its indication and regulatory path differ; a loose financing and risk-appetite comparison, not a Wilson disease valuation peer.

EPRX

Similar-sized development-stage biopharma, but product economics and indication comparability are unverified. Do not transfer its valuation multiple to MNPR.